Helus Pharma Completes Phase 3 Enrollment for HLP003 in MDD Treatment Ahead of Schedule
Event summary
- Helus Pharma completed enrollment in the Phase 3 APPROACH study for HLP003 in adjunctive treatment of Major Depressive Disorder (MDD) ahead of schedule.
- Topline data readout from the APPROACH study is on track for Q4 2026.
- HLP003 previously received Breakthrough Therapy Designation from the FDA.
- The Phase 2 data demonstrated a mean ~23-point reduction in MADRS score and 100% remission rates using recent peer-study benchmarks.
The big picture
Helus Pharma's completion of enrollment in the Phase 3 APPROACH study marks a significant step forward in developing novel serotonergic agonists for MDD. The growing adoption of innovative treatments like Johnson & Johnson’s SPRAVATO highlights the demand for effective adjunctive therapies, positioning HLP003 as a potential disruptor in the mental health treatment landscape.
What we're watching
- Regulatory Pathway
- Whether the FDA Breakthrough Therapy Designation will expedite HLP003's approval process and potential New Drug Application submission in 2028.
- Market Adoption
- The pace at which novel adjunctive treatments like HLP003 gain market share against established therapies such as Johnson & Johnson’s SPRAVATO.
- Clinical Outcomes
- How the topline data from the APPROACH study will compare to Phase 2 results, particularly in terms of durability and remission rates.